HERO Study TE: Cardiovascular Disease in Men with Prostate Cancer

HERO Study TE: Cardiovascular Disease in Men with Prostate Cancer

Search

Lower Odds of Cardiac Events for Gonadotropin Releasing Hormone Antagonists versus Agonists - Eugene Cone Details Eugene Cone, MD, a urologic oncology fellow at Harvard Medical School, joins Tom Keane, MBBCh, FRCSI, FACS, to discuss the increased risk of cardiac events associated with androgen deprivation therapy, the standard of care for prostate cancer treatment, and the differences in cardiac risk between gonadotropin-releasing antagonists versus agonists. Dr. Cone’s research compared traditional gonadotro...
The Oral GnRH Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant ADT to EBRT in Patients with Intermediate-risk Prostate Cancer - Thomas Keane Details Tom Keane discusses a recent publication in European Urology "The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant or Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localized Intermediate-risk Prostate Cancer." Dr. Keane explains that this Phase 2, open-label study demonstrated that oral once-daily relugolix, while not yet FDA a...
The Intersection of Cardiovascular Disease and Genitourinary Cancer Treatments - Javid Moslehi Details Javid Moslehi joins Alicia Morgans in a conversation on the cardiovascular health of cancer patients. Javid Moslehi's laboratory focuses on mechanistic understanding of cardiovascular toxicities that result from novel “targeted” cancer therapies. In this conversation, they discuss the cardiovascular toxicities associated with androgen deprivation therapy (ADT) and the physiologic mechanisms and ma...